Scancell’s DNA Plasmid-Cancer Vaccine Shows Promise In Melanoma
This article was originally published in Pharmaceutical Approvals Monthly
ScanCell Holdings’ potential DNA cancer vaccine, which is administered via an electrical field-driven device, shows preliminary evidence of efficacy in late-stage melanoma patients.
You may also be interested in...
Britain’s biggest drug maker updated the investment community on its pipeline prospects Dec. 3, outlining a timescale of three pipeline “waves” that will include pivotal clinical trial results on up to 14 medicines in the next two years.
Vindicated by the approvals of Provenge and Yervoy, a host of therapeutic cancer vaccines is working through late-stage trials with the regulatory finish line in sight, and some of those companies will be presenting data at the American Society of Clinical Oncology meeting in Chicago June 1-5.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.